Anti-rabies monoclonal antibody - China Medical System/Trinomab Biotech
Alternative Names: Anti-rabies monoclonal antibody - Trinomab Biotech/China Medical System; Fully human anti-rabies virus antibody - China Medical System/Trinomab Biotech; Fully human anti-rabies virus antibody - Trinomab Biotech/China Medical SystemLatest Information Update: 18 May 2023
At a glance
- Originator Trinomab Biotech
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rabies
Most Recent Events
- 18 May 2023 Trinomab Biotech has patent protection for completely humanised neutralising antibody for anti-rabies viruses in China
- 18 May 2023 Trinomab Biotech has patent protection forHitmAb® technology platform (China Medical System pipeline, May 2023)
- 21 Sep 2022 Preclinical trials in Rabies in China (Parenteral) (China Medical System pipeline, September 2022)